Hyperfine, Inc. (HYPR) Latest Company News

Sep 18, 2026, 20:13 UTC
Hyperfine, Inc. received a Nasdaq notice dated September 17, 2026 that its common stock failed to maintain the minimum $1.00 bid price required by Nasdaq Listing Rule 5450(a)(1), giving it until March 16, 2027 to regain compliance.
Sep 16, 2026, 12:00 UTC
MedtechWOMEN named Maria Sainz, President and CEO of Hyperfine, Inc., the winner of its 2026 Ferolyn Powell Leadership Award, and Beverly Tang, co-founder and CEO of Starlight Cardiovascular, the recipient of its first-ever Rising Star Award, at the MedtechVISION Annual Conference in Menlo Park, California.
Source:
- businesswire.com
Aug 26, 2026, 12:15 UTC
Hyperfine announced the publication of peer-reviewed NEURO PMR results and reported over 3,000 office brain MRI scans, supporting the growing use of the Swoop system in neurology practices during the first year of its neurology office launch.
Source:
- businesswire.com
Aug 20, 2026, 12:15 UTC
Hyperfine announced FDA clearance of its next Optive AI software, enhancing image quality, clinical utility, ease of use, and isotropic imaging capability of the Swoop system across care settings.
Source:
- businesswire.com
Aug 6, 2026, 20:05 UTC
Hyperfine, Inc. reported its second quarter 2026 financial results on August 6, 2026, highlighting growth in placements and revenue, gross margin expansion, and disciplined operating expenses.
Source:
Jul 1, 2026, 12:15 UTC
Hyperfine launched its next-generation Swoop® portable MRI system in Europe.
Source:
- businesswire.com

HYPR

Hyperfine, Inc. received a Nasdaq notice dated September 17, 2026 that its common stock failed to maintain the minimum $1.00 bid price required by Nasdaq Listing Rule 5450(a)(1), giving it until March 16, 2027 to regain compliance.

Hyperfine announced the publication of peer-reviewed NEURO PMR results and reported over 3,000 office brain MRI scans, supporting the growing use of the Swoop system in neurology practices during the first year of its neurology office launch.

Hyperfine announced FDA clearance of its next Optive AI software, enhancing image quality, clinical utility, ease of use, and isotropic imaging capability of the Swoop system across care settings.

Hyperfine, Inc. reported its second quarter 2026 financial results on August 6, 2026, highlighting growth in placements and revenue, gross margin expansion, and disciplined operating expenses.

Hyperfine launched its next-generation Swoop® portable MRI system in Europe.